XML 75 R33.htm IDEA: XBRL DOCUMENT v3.20.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
Reportable Segment Information
 
Three Months Ended
 
March 31,
(DOLLARS IN THOUSANDS)
2020
 
2019
Net sales:
 
 
 
Taste
$
830,322

 
$
804,802

Scent
516,995

 
492,600

Consolidated
$
1,347,317

 
$
1,297,402

Segment profit:
 
 
 
Taste
$
137,347

 
$
131,402

Scent
105,395

 
89,953

Global expenses
(20,393
)
 
(16,667
)
Operational Improvement Initiatives (a)
—

 
(406
)
Frutarom Integration Related Costs (b)
(3,650
)
 
(14,897
)
Restructuring and Other Charges, net (c)
(4,918
)
 
(16,174
)
(Losses) gains on sale of assets
(754
)
 
188

Frutarom Acquisition Related Costs (d)
(813
)
 
(9,529
)
Compliance Review & Legal Defense Costs (e)
(649
)
 
—

N&B Transaction Related Costs (f)
(5,199
)
 
—

N&B Integration Related Costs (g)
(10,144
)
 
—

Operating profit
196,222

 
163,870

Interest expense
(32,140
)
 
(36,572
)
Other (loss) income, net
(10,574
)
 
7,278

Income before taxes
$
153,508

 
$
134,576


(a)
Represents accelerated depreciation related to a plant relocation in India.

(b)
Represents costs related to the integration of the Frutarom acquisition. For 2020, costs primarily related to advisory services, retention bonuses and performance stock awards. For 2019, costs principally related to advisory services.
(c)
For 2020, represents costs primarily related to the Frutarom Integration Initiative. For 2019, represents costs primarily related to the Frutarom Integration Initiative and the 2019 Severance Charges program.
(d)
Represents transaction-related costs and expenses related to the acquisition of Frutarom. For 2020, amount primarily includes earn-out payments, net of adjustments, amortization for inventory "step-up" costs and transaction costs principally related to the 2019 Acquisition Activity. For 2019, amount primarily includes amortization for inventory "step-up" costs and transaction costs.
(e)
Costs related to reviewing the nature of inappropriate payments and review of compliance in certain other countries. In addition, includes legal costs for related shareholder lawsuits.
(f)
Represents transaction costs and expenses related to the pending transaction with Nutrition & Biosciences Inc.
(g)
Represents costs related to the integration of the pending transaction with Nutrition & Biosciences Inc.
Net Sales by Destination of Product Delivery
Net sales, which are attributed to individual regions based upon the destination of product delivery, were as follows:
 
Three Months Ended March 31,
(DOLLARS IN THOUSANDS)
2020
 
2019
Europe, Africa and Middle East
$
543,130

 
$
529,606

Greater Asia
309,508

 
287,962

North America
303,387

 
301,059

Latin America
191,292

 
178,775

Consolidated
$
1,347,317

 
$
1,297,402

 
Three Months Ended March 31,
(DOLLARS IN THOUSANDS)
2020
 
2019
Net sales related to the U.S.
$
270,686

 
$
272,803

Net sales attributed to all foreign countries
1,076,631

 
1,024,599